The Korean-War era Defense Production Act ("DPA")1 has already loomed large in the federal response to the COVID-19 pandemic. Recent press reports suggest that it may be invoked even more broadly in the coming weeks and...more
Competition regulators have shown their ability to act quickly and decisively in order to help allay the worst impacts of the coronavirus outbreak. Could these responses provide a template for achieving environmental and...more
9/22/2020
/ Collaboration ,
Competition ,
Competition Authorities ,
Consumers ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Environmental Policies ,
European Commission ,
Federal Trade Commission (FTC) ,
Germany ,
Grocery Stores ,
Health Care Providers ,
Netherlands ,
No-Action Letters ,
Operators of Essential Services ,
Public Safety ,
Sustainability ,
Treaty on the Functioning of the European Union (TFEU) ,
UK Competition and Markets Authority (CMA) ,
United Nations
On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical...more
4/23/2020
/ Absolute Immunity ,
Antitrust Division ,
Antitrust Provisions ,
Business Review Letters ,
Collaboration ,
Competition ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
Medical Devices ,
Medical Research ,
Medical Supplies ,
No-Action Letters ,
Personal Protective Equipment ,
Pharmaceutical Industry ,
Prescription Drugs
The Coronavirus Aid, Relief, and Economic Security ("CARES") Act provides no modifications to, or relief from, the US antitrust laws (specifically, the Sherman Act, 15 U.S.C. §§ 1-38; Clayton Act, 15 U.S.C. § 12-27; and...more